MedTrace Logo

Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

NCT04203693 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 331

Last updated 2026-03-02

Study results available
· View outcomes & findings →

Summary

The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.

Conditions

Interventions

DRUG

Tildrakizumab

The study physicians will choose the treatment independently of the enrolment in the study according to routine care.

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Study Director · Almirall, S.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-30
Primary Completion
2024-05-02
Completion
2024-05-02
FDA Drug
Yes

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04203693 on ClinicalTrials.gov